Sonelokimab not checked

MoonLake Immunotherapeutics AG · M1095

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
5 active
14 in total · 9 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
Tested for
Arthritis, Psoriatic (3 trials), Hidradenitis Suppurativa
Main trialPhase 3
“This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.”In the company’s words, NCT06641076 on ClinicalTrials.gov
Other names
M1095

Other drugs for Arthritis, Psoriatic

All 29 drugs for Arthritis, Psoriatic

Coming up3

Changes1

Last 90 days

Trials14

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 28 May 2026 Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
Phase 3Active, not recruiting 4 Jan 2027 Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Phase 3Enrolling by invitation 4 Feb 2028 A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Phase 3Enrolling by invitation 13 Jun 2028 A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3Completed 14 Aug 2025 Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3Completed 2 Sep 2025 A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3Completed 28 Sep 2026 An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
Phase 2Completed 20 Jun 2019 A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
Phase 2Completed 9 May 2023 Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Phase 2Completed 5 Sep 2023 Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
Phase 1Completed 1 Nov 2025 An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector
Phase 2Ended not given A Phase 2, multicentre open-label study to explore the effects of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris
Phase 2Ended not given A Phase 2 open-label imaging study to explore the effects of sonelokimab in patients with active axial spondyloarthritis
Phase 2Authorised not given A Phase 2, open-label, imaging study to explore the effects of sonelokimab in patients with active psoriatic arthritis or axial spondyloarthritis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Sonelokimab

Following is part of Solo: you see every change to Sonelokimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in